Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Antoni Ribas, Theresa Medina, Shivaani Kummar, et al.
Cancer Discovery (2018) Vol. 8, Iss. 10, pp. 1250-1257
Open Access | Times Cited: 274

Showing 1-25 of 274 citing articles:

Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 7-24
Closed Access | Times Cited: 1973
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi, Antoni Ribas
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 25-39
Open Access | Times Cited: 1170
Therapeutic cancer vaccines
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J.M. Melief, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 6, pp. 360-378
Closed Access | Times Cited: 1076
Harnessing innate immunity in cancer therapy
Olivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature (2019) Vol. 574, Iss. 7776, pp. 45-56
Closed Access | Times Cited: 751
Cancer vaccines: the next immunotherapy frontier
Matthew J. Lin, Judit Svensson‐Arvelund, Gabrielle S. Lubitz, et al.
Nature Cancer (2022) Vol. 3, Iss. 8, pp. 911-926
Closed Access | Times Cited: 568
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen, Natasha K. Brockwell, Belinda S. Parker
Cancers (2019) Vol. 11, Iss. 12, pp. 2002-2002
Open Access | Times Cited: 527
Improving cancer immunotherapy through nanotechnology
Michael S. Goldberg
Nature reviews. Cancer (2019) Vol. 19, Iss. 10, pp. 587-602
Closed Access | Times Cited: 524
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan‐Tong Liu, Zhi‐Jun Sun
Theranostics (2021) Vol. 11, Iss. 11, pp. 5365-5386
Open Access | Times Cited: 522
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan, Sara M. Tolaney
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 4, pp. 479-489
Open Access | Times Cited: 445
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Ignacio Melero, Eduardo Castañón, Maite Álvarez, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 558-576
Open Access | Times Cited: 344
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell (2020) Vol. 38, Iss. 4, pp. 500-515.e3
Open Access | Times Cited: 292
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Matthew D. Vesely, Tianxiang Zhang, Lieping Chen
Annual Review of Immunology (2022) Vol. 40, Iss. 1, pp. 45-74
Closed Access | Times Cited: 256
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 235
Immunotherapy, Inflammation and Colorectal Cancer
Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, et al.
Cells (2020) Vol. 9, Iss. 3, pp. 618-618
Open Access | Times Cited: 233
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 7, pp. 529-540
Closed Access | Times Cited: 232
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 224
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Chong-xian Pan, Hongtao Liu, Elizabeth Robins, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 213
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Marina Luchner, Sören Reinke, Anita Milicic
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 142-142
Open Access | Times Cited: 207
Type I interferon-mediated tumor immunity and its role in immunotherapy
Renren Yu, Bo Zhu, Degao Chen
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 3
Open Access | Times Cited: 188
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 186
Macrophage targeting in cancer
Martha Lopez‐Yrigoyen, Luca Cassetta, Jeffrey W. Pollard
Annals of the New York Academy of Sciences (2020) Vol. 1499, Iss. 1, pp. 18-41
Open Access | Times Cited: 181
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
María Ochoa de Olza, Blanca Navarro Rodrigo, Stefan Zimmermann, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 9, pp. e419-e430
Closed Access | Times Cited: 178
The role of dendritic cells in cancer and anti-tumor immunity
Ariel E. Marciscano, Niroshana Anandasabapathy
Seminars in Immunology (2021) Vol. 52, pp. 101481-101481
Open Access | Times Cited: 168
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu
Immunity (2020) Vol. 52, Iss. 1, pp. 36-54
Open Access | Times Cited: 166
Mechanisms of immune activation and regulation: lessons from melanoma
Shelly Kalaora, Adi Nagler, Jennifer A. Wargo, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 4, pp. 195-207
Closed Access | Times Cited: 166
Page 1 - Next Page

Scroll to top